Legend Biotech Corp

These Funding Advances are accounted for as interest-bearing borrowings funded by Janssen, constituted by a principal amounting to $ 250.0 million and applicable interests accrued amounting to $ 73.3 million upon such principal as of March 31, 2026.

SEC original ↗Legend Biotech Corp — Earnings release (6-K report)6-KMay 12, 2026

The respective interest rate of each borrowing has transitioned from London Interbank Offered Rate (LIBOR) to Secured Overnight Financing Rate (SOFR) in accordance with the LIBOR ACT.

SEC original ↗Legend Biotech Corp — Earnings release (6-K report)6-KMay 12, 2026

Under PRC regulations, foreign-invested enterprises may pay dividends only out of their accumulated profit, if any, as determined in accordance with PRC accounting standards and regulations.

SEC original ↗Legend Biotech Corp — Earnings release (6-K report)6-KMay 12, 2026

Although we do not currently require any such dividends from our PRC subsidiaries to fund our operations, should we require additional sources of liquidity in the future, such restrictions may have a material adverse effect on our liquidity and capital resources.

SEC original ↗Legend Biotech Corp — Earnings release (6-K report)6-KMay 12, 2026

B-Business Overview - Government Regulation - PRC Regulation - Other PRC National- and Provincial-Level Laws and Regulations - Regulations Relating to Dividend Distributions in our Annual Report on Form 20-F for the year ended December 31, 2025.

SEC original ↗Legend Biotech Corp — Earnings release (6-K report)6-KMay 12, 2026

To supplement our cash proceeds from the product revenue, we might need to finance our cash through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements.

SEC original ↗Legend Biotech Corp — Earnings release (6-K report)6-KMay 12, 2026

Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our financial needs, our operational results and other future conditions.

SEC original ↗Legend Biotech Corp — Earnings release (6-K report)6-KMay 12, 2026

Our lead product candidate, ciltacabtagene autoleucel, ("cilta-cel") (referred to 15 as LCAR-B38M for purposes of our LEGEND-2 trial), is a CAR-T cell therapy we are jointly developing with our strategic partner, Janssen Biotech, Inc.

SEC original ↗Legend Biotech Corp — Earnings release (6-K report)6-KMay 12, 2026

We believe we have established robust sourcing strategies for all necessary materials and do not expect any significant impact.

SEC original ↗Legend Biotech Corp — Earnings release (6-K report)6-KMay 12, 2026

The increase of $105.9 million was primarily due to Legend Biotech s share of the cost of sales in connection with CARVYKTI sales under the Janssen Agreement, as well as one-time additional costs incurred for capacity expansion and depreciation charges.

SEC original ↗Legend Biotech Corp — Earnings release (6-K report)6-KMay 12, 2026

The increase of $9.1 million was primarily due to higher commercial costs, including sales force expansion and Janssen-related marketing and market access activities, which rose with collaboration revenue.

SEC original ↗Legend Biotech Corp — Earnings release (6-K report)6-KMay 12, 2026

These forward-looking statements involve various risks and uncertainties.

SEC original ↗Legend Biotech Corp — Earnings release (6-K report)6-KMay 12, 2026

litigation process; the impact of U.

SEC original ↗Legend Biotech Corp — Earnings release (6-K report)6-KMay 12, 2026

In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all.

SEC original ↗Legend Biotech Corp — Earnings release (6-K report)6-KMay 12, 2026

Changes in tariffs, supply chain constraints, logistics challenges, labor shortages, international tension and conflicts and steps taken by governments and central banks, have led to fluctuating inflation, which has led to an increase in costs and has caused changes in fiscal and monetary policy, including fluctuating interest rates.

SEC original ↗Legend Biotech Corp — Earnings release (6-K report)6-KMay 12, 2026

Specifically with respect to the current tariffs imposed by the Trump administration, we do not currently believe such tariffs will have a material impact on our financial condition, as pharmaceuticals were exempted from these tariffs.

SEC original ↗Legend Biotech Corp — Earnings release (6-K report)6-KMay 12, 2026

However, the Trump administration has announced an intention to implement tariffs for pharmaceuticals at a future date.

SEC original ↗Legend Biotech Corp — Earnings release (6-K report)6-KMay 12, 2026